| Document |
Document Title |
|
WO/2023/176609A1 |
This composition includes an infrared absorbing agent, a curable compound, and a solvent, wherein the infrared absorbing agent includes a compound represented by formula (1). Provided are a film, an optical filter, a solid-state imaging ...
|
|
WO/2023/177184A1 |
The present invention relates to: a compound, represented by chemical formula 1, for an organic optoelectronic device; an organic optoelectronic device comprising same; and a display device. The details of chemical formula 1 are as defin...
|
|
WO/2023/174235A1 |
Disclosed are a compound represented by formula (I) as a mutant isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) inhibitor, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed is a use of the described...
|
|
WO/2023/176957A1 |
The present invention provides a compound which is used for the treatment of a fungal infection, including a topical fungal infection and a systemic fungal infection, caused by fungi belonging to the genus Trichophyton, the genus Candida...
|
|
WO/2023/177568A1 |
The application relates to compounds of the general Formula (I) which act as cannabinoid receptor modulators useful for the treatment of complications arising from metabolic, inflammatory and fibrotic disorders.
|
|
WO/2023/170025A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compo...
|
|
WO/2023/169453A1 |
The present invention relates to a heteroaromatic ring-containing alkynyl compound, and a preparation method therefor and the use thereof. The heteroaromatic ring-containing alkynyl compound is a compound represented by a formula (I), or...
|
|
WO/2023/171788A1 |
The present invention addresses the problem of providing: a photoelectric conversion element which is excellent in production applicability and also excellent in photoelectric conversion efficiency; an imaging element; a photosensor; and...
|
|
WO/2023/168908A1 |
Disclosed are fused quinone oxime imidazole, an onium derivative thereof, a preparation therefor and a use thereof. The structure of the fused quinone oxime imidazole is represented by the following general formulas (I), (II), (III) and ...
|
|
WO/2023/171920A1 |
Provided is a high-refractive-index carbazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...
|
|
WO/2023/171934A1 |
The present invention relates to a novel organic compound and an organic light-emitting device comprising same. More specifically, the present invention provides an organic electroluminescent device which has low driving voltage and is s...
|
|
WO/2023/169436A1 |
Disclosed in the present invention are a benzo bicyclic compound, and a preparation method and application thereof. Specifically disclosed is a compound, which is a compound as shown in formula (X), or a stereoisomer, geometric isomer, t...
|
|
WO/2023/169481A1 |
The present invention provides a tetrahydroisoquinoline derivative as a pan-KRAS inhibitor. Specifically, the present invention provides a tetrahydroisoquinoline derivative having a structural formula as shown in general formula (I) and ...
|
|
WO/2023/168240A1 |
The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myoca...
|
|
WO/2023/165523A1 |
Disclosed in the present invention are an aromatic ring substituted methoxy derivative and a use thereof. The aromatic ring substituted methoxy derivative has a structure as shown in formula I, and is expected to be used for treating tum...
|
|
WO/2023/165943A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/165403A1 |
A composition, an organic light-emitting device, and a display apparatus. The composition comprises at least two compounds each having a structure represented by formula I. By designing the components of the composition, further using to...
|
|
WO/2023/166067A1 |
A compound of Formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2023/159307A1 |
Disclosed are compounds and pharmaceutically acceptable salts of formula (I), which feature either a N-(1H-pyrazol-3-yl)pyridin-2-amine or a N-(1H-pyrazol-3-yl)pyrimidin-4-amine core structure. These compounds may be used in the treatmen...
|
|
WO/2023/164358A1 |
The present application describes GLP-IR modulating compounds that are useful for treating GLP-IR-mediated diseases or conditions.
|
|
WO/2023/163140A1 |
The purpose of the present invention is to provide a compound that exhibits an H-PGDS inhibitory activity. The present invention relates to a compound expressed by formula [I] or a pharmaceutically acceptable salt thereof (in the formula...
|
|
WO/2023/163479A1 |
The present invention relates to a novel compound with excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device that includes the compound in at least one organic materi...
|
|
WO/2023/161172A1 |
The present invention relates to substituted N-benzoic acid uracils of general formula (I) or salts thereof, wherein the radicals in general formula (I) correspond to the definitions given in the description, and to the use thereof as he...
|
|
WO/2023/161316A1 |
The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A, X, R1-R9, R12 and R13 are as described herein (I). Further provided are pharmaceutical ...
|
|
WO/2023/163381A1 |
The present specification relates to a heterocyclic compound of chemical formula 1, and an organic light-emitting device and an organic material layer formation composition which comprise same.
|
|
WO/2023/160121A1 |
The present application belongs to the technical field of organic materials. Provided are an organic compound, an electronic element comprising same, and an electronic device, wherein the organic compound has a structure as represented b...
|
|
WO/2023/164612A1 |
Disclosed herein are compounds (I) and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of d...
|
|
WO/2023/070987A9 |
Provided are an organic compound, an organic electroluminescent device comprising same, and an electronic apparatus, relating to the field of organic electroluminescence. The structure of the organic compound is as shown in formula 1, an...
|
|
WO/2023/155710A1 |
The present invention belongs to the field of medicinal chemistry, and relates to an IKZF2 degradation agent, a pharmaceutical composition comprising same and use thereof. Specifically, the IKZF2 degradation agent has a structure represe...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2022/129589A9 |
The present disclosure relates to novel compounds of formula (I) which are useful as inhibitors of endoplasmic reticulum aminopeptidases (ERAP), in particular as inhibitors of ERAP2. The disclosure also relates to the therapeutic use of ...
|
|
WO/2023/153795A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/152063A1 |
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, particularly organic electroluminescent devices, containing these compounds.
|
|
WO/2023/154913A1 |
The present invention relates to sulfonamides and related compounds which are inhibitors of PARG and are useful in the treatment of cancer.
|
|
WO/2023/152346A1 |
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, more particularly organic electroluminescent devices, containing these compounds.
|
|
WO/2023/153748A1 |
The present invention relates to an SOS1 inhibitor and a derivative thereof. A compound, or a pharmaceutically acceptable salt, hydrate, solvate, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof of the present in...
|
|
WO/2023/152042A1 |
A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, substituted in the 6-position by an arylphenyl or heteroarylphenyl moiety, being potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in h...
|
|
WO/2023/154519A1 |
Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/153169A1 |
The present disclosure provides an organic compound represented by general formula (1). (In general formula (1), R1 to R20 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, an...
|
|
WO/2023/154310A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
|
|
WO/2023/151394A1 |
The present invention relates to the technical field of organic electroluminescent materials, and in particular, to a fluorene derivative and a use thereof. The structural formula of the fluorene derivative is shown in formula (I). The f...
|
|
WO/2023/151359A1 |
Provided are a tetrahydrocarbazole derivative represented by general formula (I) as well as a preparation method therefor and the use thereof. By means of design of the molecular structure, the tetrahydrocarbazole derivative has an excel...
|
|
WO/2023/153906A1 |
The present invention relates to: a compound, represented by chemical formula 1, for an organic optoelectronic device; a composition for an organic optoelectronic device; an organic optoelectronic device comprising same; and a display ap...
|
|
WO/2023/150776A1 |
The present disclosure provides water-soluble and low-aggregation NIR- and SWIR- active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.
|
|
WO/2023/150525A1 |
Arylsulfonamides of 4-substituted-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such a...
|
|
WO/2023/143605A1 |
The invention provides a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially KRAS G12C inhibitors.The present invention provides a direct enantioselective ch...
|
|
WO/2023/146785A1 |
The present disclosure provides compounds of the formula (III) and their pharmaceutically acceptable salts, and compounds of the formula (IV) and their pharmaceutically acceptable salts, and pharmaceutical compositions comprising these c...
|
|
WO/2023/146343A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/146344A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/145535A1 |
This resist composition contains a resin component having a structural unit derived from a compound represented by general formula (a0-1) or a structural unit derived from a compound represented by general formula (a0-2). In the formulae...
|
